Seguridad de las vacunas contra la COVID-19 / COVID-19 vaccine safety
Rev. peru. med. exp. salud publica
; 38(4): 634-642, oct.-dic. 2021. tab, graf
Article
in Spanish
| LILACS
| ID: biblio-1365939
Responsible library:
PE14.1
RESUMEN
RESUMEN El desarrollo y producción de vacunas seguras y eficaces contra la enfermedad por coronavirus 2019 (COVID-19) ofrece la esperanza para el control de la pandemia actual. Los eventos adversos posteriores a la inmunización son respuestas indeseadas o acontecimientos involuntarios que siguen a la vacunación, y que deben ser cuidadosamente vigilados, ya que todas las vacunas, incluyendo las desarrolladas contra el SARS-CoV-2, requieren cumplir con los criterios de seguridad para su administración en humanos. Se recopiló la información de la base de datos de PubMed/Medline durante los meses de agosto de 2020 a noviembre de 2021. La mayoría de los eventos adversos identificados en los ensayos clínicos fueron leves o moderados; sin embargo, se identificaron eventos trombóticos asociados a algunas vacunas basadas en vectores virales contra la COVID-19 en estudios de seguimiento, aunque se requiere la conclusión de los distintos estudios en curso y vigilancia poscomercialización para determinar todos los posibles eventos adversos y de especial interés.
ABSTRACT
ABSTRACT The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest.
Adverse events; Clinical Trial; Coronavirus; Coronavirus; Efficacy; Eficacia; Ensayo Clínico; Ensayo clínico en Fase III; Eventos adversos; Glicoproteína de la Espiga del Coronavirus; Immunogenicity; Inmunogenicidad; Pandemia; Pandemics; Phase III; SARS-CoV-2; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccine; Vacuna
Full text:
Available
Collection:
International databases
Health context:
SDG3 - Target 3.3 End transmission of communicable diseases
Health problem:
Pneumonia
Database:
LILACS
Main subject:
Efficacy
/
Clinical Trial, Phase III
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Rev. peru. med. exp. salud publica
Journal subject:
Public Health
Year:
2021
Document type:
Article
Affiliation country:
Bolivia
/
Cuba
Institution/Affiliation country:
Hospital Clínico Quirúrgico Docente «Salvador Allende¼/CU
/
PROSALUD/BO
/
Universidad Franz Tamayo/BO